Rowlandmiller & Partners’s Pfizer PFE Stock Holding History

Rowlandmiller & Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92M	Buy	79,826 +2,131	+3%	+$55.7K	0.35%	67
2026 Q1	$2.18M	Sell	77,695 -4,043	-5%	-$108K	0.44%	52
2025 Q4	$2.04M	Sell	81,738 -382	-0.5%	-$9.63K	0.39%	58
2025 Q3	$2.09M	Buy	82,120 +1,903	+2%	+$47K	0.41%	57
2025 Q2	$1.94M	Sell	80,217 -177	-0.2%	-$4.13K	0.4%	58
2025 Q1	$2.04M	Sell	80,394 -2,449	-3%	-$64.1K	0.43%	53
2024 Q4	$2.2M	Sell	82,843 -1,266	-2%	-$34.3K	0.46%	51
2024 Q3	$2.43M	Buy	84,109 +902	+1%	+$26.3K	0.49%	51
2024 Q2	$2.33M	Buy	83,207 +4,339	+6%	+$119K	0.51%	51
2024 Q1	$2.19M	Buy	78,868 +9,702	+14%	+$269K	0.46%	53
2023 Q4	$1.99M	Sell	69,166 -1,775	-3%	-$53.7K	0.46%	54
2023 Q3	$2.35M	Sell	70,941 -1,269	-2%	-$44.9K	0.58%	48
2023 Q2	$2.65M	Sell	72,210 -1,705	-2%	-$66.4K	0.63%	45
2023 Q1	$3.02M	Buy	73,915 +323	+0.4%	+$14K	0.73%	39
2022 Q4	$3.77M	Sell	73,592 -368	-0.5%	-$17.6K	0.93%	36
2022 Q3	$3.24M	Buy	73,960 +67	+0.1%	+$3.26K	0.87%	36
2022 Q2	$3.87M	Buy	73,893 +34	+0%	+$1.73K	0.99%	33
2022 Q1	$3.82M	Sell	73,859 -437	-0.6%	-$22.7K	0.89%	36
2021 Q4	$4.39M	Buy	74,296 +12,571	+20%	+$623K	0.98%	33
2021 Q3	$2.02M	Sell	61,725 -11,089	-15%	-$491K	0.68%	42
2021 Q2	$2.85M	Buy	72,814 +5,149	+8%	+$200K	0.7%	42
2021 Q1	$2.45M	Buy	67,665 +3,271	+5%	+$116K	0.64%	47
2020 Q4	$2.37M	Sell	64,394 -415	-0.6%	-$15.2K	0.68%	42
2020 Q3	$2.01M	Sell	64,809 -249	-0.4%	-$8.73K	0.8%	36
2020 Q2	$2.02M	Buy	65,058 +249	+0.4%	+$8.46K	0.68%	42
2020 Q1	$2.01M	Sell	64,809 -395	-0.6%	-$13.5K	0.8%	36
2019 Q4	$2.42M	Buy	65,204 +485	+0.7%	+$17.3K	0.75%	41
2019 Q3	$2.22M	Buy	64,719 +1,555	+2%	+$56.5K	0.75%	42
2019 Q2	$2.58M	Buy	63,164 +132	+0.2%	+$5.24K	0.9%	38
2019 Q1	$2.54M	Sell	63,032 -1,071	-2%	-$42.9K	0.91%	36
2018 Q4	$2.65M	Buy	64,103 +2,144	+3%	+$89K	1.08%	32
2018 Q3	$2.59M	Sell	61,959 -1,969	-3%	-$75.8K	0.94%	33
2018 Q2	$2.2M	Buy	63,928 +5	+0%	+$171	0.86%	38
2018 Q1	$2.14M	Buy	63,923 +676	+1%	+$23.2K	0.85%	38
2017 Q4	$2.18M	Sell	63,247 -839	-1%	-$28.6K	0.85%	41
2017 Q3	$2.16M	Sell	64,086 -1,862	-3%	-$59.8K	0.9%	39
2017 Q2	$2.1M	Sell	65,948 -436	-0.7%	-$13.8K	0.89%	40
2017 Q1	$2.15M	Buy	66,384 +1,518	+2%	+$47.9K	0.95%	38
2016 Q4	$2M	Sell	64,866 -65	-0.1%	-$1.98K	0.9%	38
2016 Q3	$2.09M	Sell	64,931 -1,290	-2%	-$43.1K	0.97%	39
2016 Q2	$2.21M	Sell	66,221 -130	-0.2%	-$4.15K	1.02%	38
2016 Q1	$1.87M	Buy	66,351 +2,941	+5%	+$84K	0.88%	40
2015 Q4	$1.91M	Buy	63,410 +378	+0.6%	+$11.9K	0.97%	33
2015 Q3	$1.87M	Sell	63,032 -1,289	-2%	-$41.3K	0.99%	36
2015 Q2	$2.05M	Sell	64,321 -824	-1%	-$26.9K	1.02%	37
2015 Q1	$2.13M	Sell	65,145 -2,141	-3%	-$68.1K	1.06%	36
2014 Q4	$1.99M	Buy	+67,286	New	+$1.93M	0.96%	33

Other funds holding PFE

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

SLAM

Swiss Life Asset Management Zurich $24.1B AUM 38.82% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Rowlandmiller & Partners's PFE Position: Q2 2026 in Review

Rowlandmiller & Partners increased its Pfizer (PFE) stake by 2.7% in Q2 2026, buying an estimated $55.7K and bringing the position to 79,826 shares worth $1.92M. The position accounts for 0.35% of the portfolio, ranked #67.

Rowlandmiller & Partners first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $4.39M in Q4 2021. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Rowlandmiller & Partners held 79,826 shares of Pfizer worth $1.92M as of Q2 2026.
Rowlandmiller & Partners bought 2,131 Pfizer shares in Q2 2026, an estimated $55.7K.
Pfizer made up 0.35% of Rowlandmiller & Partners's portfolio in Q2 2026, its #67 holding.
Rowlandmiller & Partners first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
Rowlandmiller & Partners's Pfizer position peaked at $4.39M in Q4 2021.
1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Rowlandmiller & Partners's 13F filing for Q2 2026, filed 23 Jul 2026.